Phase 2 patients assigned initially to BCG re-treatment who are noted to have persistent or recurrent high grade NMIBC (Tis, Ta, or T1) at any post-treatment study evaluation have converted their disease status from BCG-relapsing to BCG-unresponsive. Such patients continue to meet study eligibility criteria, they may cross-over to durvalumab monotherapy treatment.